Agilent Technologies (NYSE:A) Price Target Raised to $150.00 at TD Cowen

Agilent Technologies (NYSE:A) had its price objective raised by equities researchers at TD Cowen to $150.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would suggest a potential upside of 34.13% from the stock’s previous close.

Several other equities research analysts also recently issued reports on A. Wells Fargo & Company reduced their price objective on Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a research note on Thursday, April 17th. Barclays reduced their price objective on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Jefferies Financial Group reduced their price objective on Agilent Technologies from $135.00 to $116.00 and set a “hold” rating for the company in a research note on Monday, April 21st. Finally, Robert W. Baird reduced their price objective on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating for the company in a research note on Thursday, May 22nd. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.15.

Agilent Technologies Trading Down 1.3%

Shares of NYSE A opened at $111.83 on Thursday. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a market cap of $31.88 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 3.13 and a beta of 1.27. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $108.44 and a 200-day simple moving average of $126.47.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.05. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.63 billion. Agilent Technologies had a return on equity of 26.13% and a net margin of 17.59%. The business’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.22 EPS. Sell-side analysts predict that Agilent Technologies will post 5.54 EPS for the current year.

Insiders Place Their Bets

In other news, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the transaction, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84% decrease in their position. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Global X Japan Co. Ltd. increased its holdings in shares of Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 116 shares during the last quarter. Redwood Park Advisors LLC bought a new stake in Agilent Technologies during the 4th quarter valued at approximately $27,000. Lee Danner & Bass Inc. bought a new stake in Agilent Technologies during the 4th quarter valued at approximately $29,000. Sunbelt Securities Inc. boosted its stake in Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 192 shares during the period. Finally, Whipplewood Advisors LLC boosted its stake in Agilent Technologies by 286.2% during the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 186 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.